From the clip:
“We are excited to test sozinibercept in large P3 programmes […] with the goal of […] showing that we can improve visual acuity hopefully by up to 5 letters or more.“
To my memory, this is the first time somebody sharing responsibility for running the trials dares to explicitly mention a „5 letters or more“ improvement as what OPT internally is really hoping for. If this hope materializes then Eichenbaum is absolutely right saying that sozinibercept would disrupt the wAMD market.
I just cannot believe existing players continuing to stay quiet with this disruptive opportunity being up for sale / partnership just 15 months ahead of P3 results. Therefore, I’d indeed expect a partnership occurring over the next 3 months being more probable than a classic CR.
- Forums
- ASX - By Stock
- OPT
- Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024
Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024, page-42
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
(20min delay)
|
|||||
Last
41.0¢ |
Change
0.005(1.23%) |
Mkt cap ! $504.7M |
Open | High | Low | Value | Volume |
41.5¢ | 42.0¢ | 40.0¢ | $458.6K | 1.119M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 298731 | 41.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
41.5¢ | 49490 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 266550 | 0.410 |
8 | 176806 | 0.405 |
11 | 205071 | 0.400 |
8 | 205711 | 0.395 |
9 | 140810 | 0.390 |
Price($) | Vol. | No. |
---|---|---|
0.415 | 49490 | 1 |
0.420 | 181330 | 5 |
0.425 | 20000 | 1 |
0.440 | 13031 | 2 |
0.445 | 1 | 1 |
Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |